BOLD-100
id:
bold-100-246-15864831
title:
BOLD-100
text:
BOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is a ruthenium-based anti-cancer therapeutic in clinical development. As of February 2024, BOLD-100 was being tested in a Phase 1b/2a clinical trial in 117 patients with advanced gastrointestinal cancers in combination with the chemotherapy regimen FOLFOX. BOLD-100 is being developed by Bold Therapeutics Inc.
brand slug:
wiki
category slug:
encyclopedia
description:
Experimental cancer drug
original url:
https://en.wikipedia.org/wiki/BOLD-100
date created:
date modified:
2024-02-21T19:49:16Z
main entity:
{"identifier":"Q111049053","url":"https://www.wikidata.org/entity/Q111049053"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/d/d8/BOLD-100.svg","width":440,"height":720}
fields total:
13
integrity:
15